Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

An Annual Review of Important Apheresis Articles From the American Society for Apheresis Attending Physician Subcommittee
Tanhehco, Yvette C. , Alsammak, Mohamed , Wu, Ding Wen , Costa, Victoria, Chhibber, Vishesh, Li, Yanhua , Lu, Wen , Stephens, Laura D. , Noland, Daniel K., Martin, Marisa C. Saint, Zantek, Nicole D. , Becker, Joanne , Wehrli, Gay , Levenbrown, Yosef , Lu, Wen , Stephens, Laura , Zantek, Nicole D , Wu, Ding Wen , Mattiazzi, Adela D. , Singh, Nirupama

Journal of Clinical Apheresis | November 20, 2024 | Volume: 39 | Issue: 6 | Pages: No page available

10.1002/jca.22152 | PMID 39564880 Get It

ABSTRACTIn this first annual review article, the American Society for Apheresis (ASFA) Attending Physician Subcommittee (APSc) of the Physicians' Committee (PC) curated key apheresis literature in 2023 and presented their choices for the 10 most seminal apheresis articles. PubMed and OVID search engines were used to identify manuscripts from four topic areas: donor apheresis, therapeutic apheresis, education, and cellular therapy. To further identify seminal criteria, they had to present at least one of the following: novel findings, practice‐altering outcomes, international scope, randomized controlled trial, relevant to current clinical practice, and/or provide evidence for category III or IV indications based on the ASFA ninth special issue of the Guidelines on the Use of Therapeutic Apheresis in Clinical Practice‐Evidence‐Based Approach. Inclusion criteria included: full‐length, peer‐reviewed, English language, and human subjects. Case reports, review articles, and meta‐analyses were excluded.
Bioengineered Human Arteries for the Repair of Vascular Injuries in an Extremity Injury Subset of Trial Participants
Moore, Ernest E. , Kundi, Rishi, Rajani, Ravi R. , Sokolov, Oleksandr , Niklason, Laura E. , Khondker, Zakaria, Parikh, Shamik , Investigators, CLN-PRO-V005 Investigators and the CLN-PRO-V017, Kundi, Rishi, Brenner, Megan , Lum, Ying Wei, Namias, Nicholas, Fujitani, Roy M. , Magee, Gregory A. , Batista, Philip M. , Trani, Jose, Oresanya, Lawrence , Sjoholm, Lars Ola, Calero, Aurelia, Seamon, Mark J. , Malas, Mahmoud B. , Clouse, Darrin, Naslund, Thomas C., Callcut, Rachael A. , Grandas, Oscar H., Skarupa, David , Southerland, Kevin W. , Freeman, Carl, Hurie, Justin , Goldin, Ilya, Karram, Tony, Greenberg, George, Halak, M., Skupyy, Oleh, Yurets, Serhii, Stanko, Oleksandr , Curi, Michael A. , Namias, Nicholas , Kundi, Rishi, Lum, Ying Wei , Fox, Charles J. , Rasmussen, Todd E. , Investigators, CLN-PRO-V005 Investigators and the CLN-PRO-V017, Kundi, Rishi, Morrison, Jonathan J. , Lum, Ying Wei, Shores, Jaimie T. , Namias, Nicholas, Schreiber, Martin J. , Halak, Moshe, Shaprynskyi, Vasyl V.

JAMA Surgery | November 20, 2024 | Volume: 160 | Issue: 2 | Pages: 181

10.1001/jamasurg.2024.4893 | PMID 39565635 Get It

Importance Vascular injuries require urgent repair to minimize loss of limb and life. Standard revascularization relies on autologous vein or synthetic grafts, but alternative options are needed when adequate vein is not feasible and when clinical conditions preclude safe use of synthetic materials. Objective To evaluate the performance of the acellular tissue engineered vessel (ATEV) in the repair of extremity arterial injuries. Design, Setting, and Participants Two open-label, single-arm, nonrandomized clinical trials, including 1 prospective civilian study (CLN-PRO-V005 [V005]) and 1 retrospective observational study in a war zone (CLN-PRO-V017 [V017]), were conducted from September 2018 to January 2024 (follow-up ongoing) at 19 level 1 trauma centers in the US and Israel and 5 frontline hospitals in Ukraine. Patients had vascular injury, no autologous vein available for emergent revascularization, and risk factors for wound infection. Data include the subset of patients with extremity injuries and were analyzed from September 2023 to January 2024. Intervention The ATEV is a bioengineered vascular conduit grown from human vascular cells, available off the shelf, and implantable without immunosuppression. Main Outcomes and Measures Primary patency at day 30 was the primary outcome. Secondary outcomes included limb salvage, graft infection, and patient survival. A systematic literature review identified synthetic graft benchmarks in the treatment of arterial trauma for the same end points. Results The arterial extremity injury subset included 51 of 69 participants in V005 and 16 of 17 participants in V017. The majority were male (V005, 38 [74.5%]; V017, 16 [100%]), the mean (SD) ages were similar (V005, 33.5 [13.6] years; V017, 34.2 [9.0] years), and the mean (SD) Injury Severity Scores were similar (V005, 20.8 [10.5]; V017, 20.1 [18.9]). Penetrating injuries dominated (V005, 29 patients [56.9%]; V017, 14 patients [87.5%]). At day 30 for the V005 and V017 trials, respectively, ATEV primary patency was 84.3% (95% CI, 72.0%-91.8%) and 93.8% (95% CI, 71.7%-98.9%); secondary patency was 90.2% (95% CI, 79.0%-95.7%) and 93.8% (95% CI, 71.7%-98.9%); amputation rate was 9.8% (95% CI, 4.3%-21.0%) and 0% (95% CI, 0.0%-19.4%); ATEV infection rate was 2.0% (95% CI, 0.4%-10.3%) and 0% (95% CI, 0.0%-19.4%); and death rate was 5.9% (95% CI, 2.0%-15.9%) and 0% (95% CI, 0.0%-19.4%) (no deaths attributed to the ATEV at day 30). Day 30 synthetic graft benchmarks were as follows: secondary patency, 78.9%; amputation, 24.3%; infection, 8.4%; and death, 3.4%. Conclusions and Relevance Results of analysis in the subset of patients with vascular extremity injuries in 2 single-arm trials in civilian and real-world military settings suggest that the ATEV provides benefits in terms of patency, limb salvage, and infection resistance. Comparing ATEV outcomes with synthetic graft benchmarks demonstrated improved outcomes in the treatment of acute vascular injuries of the extremities. The analyses reported herein are limited to the subset of 67 patients with vascular extremity injuries out of 86 patients enrolled in 2 trials and excluded 19 patients with iatrogenic and torso injuries. Had these 19 patients been included in these analyses, the efficacy and safety findings could have been attenuated. Trial Registration ClinicalTrials.gov Identifiers: NCT03005418 , NCT05873959
Electrophysiologic Considerations in Adult Patients with Ebstein’s Anomaly
Hsiung, Ingrid , Fatunde, Olubadewa A. , Madhavan, Malini , Majdalany, David , Majdalany, David S , Fatunde, Olubadewa A , Srivathsan, Komandoor

Journal of Personalized Medicine | November 20, 2024 | Volume: 14 | Issue: 11 | Pages: 1113

10.3390/jpm14111113 | PMID 39590605 Get It

Ebstein’s anomaly (EA) is a rare cyanotic form of congenital heart disease (CHD) characterized by apical displacement of the tricuspid valve, with resultant hemodynamic and electrical manifestations. The severity of symptoms is determined by the degree of apical displacement and deformity and incompetence of the tricuspid valve. As a result, patients with EA can be severely symptomatic during infancy and childhood or can be incidentally discovered in the sixth or seventh decade of life. Hallmarks of Ebstein’s anomaly include progressive cyanosis, right-sided heart failure, and tachyarrhythmias, among which tachyarrhythmias (most commonly atrial, but also ventricular) are the most common presenting symptoms in Ebstein’s anomaly patients during adulthood. This review aims to provide insight into the genetic and electrophysiological (EP) basis underlying the tachyarrhythmias encountered when managing patients with EA.
Senescence Biomarkers and Trajectories of Frailty and Physical Function After Kidney Transplantation
Lorenz, Elizabeth C. , Smith, Byron H. , Wadei, Hani M. , Mour, Girish , Kennedy, Cassie C. , Schinstock, Carrie A. , Kremers, Walter K. , Cheville, Andrea , Hickson, LaTonya J. , Atkinson, Elizabeth J. , White, Thomas A. , Cheville, Andrea L , Rule, Andrew D , LeBrasseur, Nathan K , Smith, Byron , Hickson, LaTonya J , Schinstock, Carrie , Kennedy, Cassie C , Wadei, Hani M , Kremers, Walter K , Mour, Girish K , Rule, Andrew D. , LeBrasseur, Nathan K.

Clinical Transplantation | November 20, 2024 | Volume: 38 | Issue: 11 | Pages: No page available

10.1111/ctr.70022 | PMID 39564682 Get It

ABSTRACTCellular senescence is a biological mechanism of aging and age‐related diseases. The aim of this study was to examine whether senescence biomarkers are associated with frailty and physical function trajectories in patients undergoing kidney transplantation (KT). We also discussed the relationship between senescence biomarkers and KT function. In this multicenter study, we prospectively assessed plasma levels of senescence biomarkers, frailty as measured by the Physical Frailty Phenotype, and physical function as measured by the Short Physical Performance Battery prior to KT. Frailty, physical function, and KT function were also measured 1 year after KT. Variable associations were assessed using Cox and relaxed least absolute shrinkage and selection operation regression. The cohort consisted of 197 participants (mean age 53 ± 13 years, 61.4% male, and 80.2% White race). Higher pre‐KT levels of macrophage‐derived chemokine (MDC/CCL22) and growth differentiation factor‐15 (GDF‐15) were independently associated with less improvement in frailty and/or physical function during the first year after KT. Higher pre‐KT levels tumor necrosis factor receptor superfamily member 6 (FAS) and MMP‐9 levels were independently associated with lower KT function one year after KT. Pre‐KT cellular senescence may contribute to frailty, physical function, and kidney function trajectories during the first year after KT.
Secukinumab in bio‐experienced patients with moderate‐to‐severe hidradenitis suppurativa from a single center: an observational retrospective study
Tran, Thuy M., Tran, Thuy M., Akpala, Christeebella O. , Tran, Tung S. , Davis, Mark , Baum, Christian L. , Wetter, David A., Nguyen, Giang Huong , Akpala, Christeebella O , Tran, Tung S , Davis, Mark Denis P., Nguyen, Giang H , Tran, Thuy M., Tran, Thuy M., Davis, Mark Denis P., Alavi, Afsáneh , Wetter, David A.

International Journal of Dermatology | November 20, 2024 | Volume: 64 | Issue: 5 | Pages: 949-951

10.1111/ijd.17583 | PMID 39564701 Get It

The atypical faces of optic neuritis: neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease
Poonja, Sabrina, Chen, John J., Chen, John J. , Chen, John J , Poonja, Sabrina , Rattanathamsakul, Natthapon

Current Opinion in Neurology | November 20, 2024 | Volume: 38 | Issue: 1 | Pages: 96-104

10.1097/wco.0000000000001335 | PMID 39564614 Get It

Purpose of review The purpose of this article is to provide a review of neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), with a focus on what renders optic neuritis “atypical” in these two conditions. Clinical features, diagnostic criteria, and epidemiology are outlined. Acute treatments for optic neuritis, as well as immunotherapy for NMOSD and MOGAD are discussed. Recent findings Updates in NMOSD and MOGAD are highlighted, with an emphasis on novel work including the new 2023 MOGAD diagnostic criteria, our evolving understanding on the epidemiology of these conditions, and recently FDA-approved NMOSD treatments. Pipeline therapies are also discussed. Summary A thorough history and examination, supported by ancillary testing, continues to be the mainstay of optic neuritis diagnosis. Stratifying typical versus atypical optic neuritis is paramount. Within the atypical category, NMOSD and MOGAD are important considerations. Clues can point towards these diagnoses and guide steps for treatment, which is increasingly becoming targeted to individual diseases, as the pathophysiology is different for these disorders.
American Foregut Society White Paper on the Endoscopic Assessment of the Gastroesophageal Valve After Anti-Reflux Surgery
Nguyen, Ninh T. , Bell, Reginald , Chang, Kenneth J. , Lipham, John C. , Hinojosa, Marcelo W. , Brunaldi, Vitor , Dunst, Christy M. , Mittal, Ravinder K., Oelschlager, Brant K. , Houghton, Caitlin, Schnoll‐Sussman, Felice , Kahrilas, Peter J., Dayyeh, Barham K. Abu , Buckley, Francis Paul, Kahrilas, Peter J.

Foregut: The Journal of the American Foregut Society | November 20, 2024 | Volume: 5 | Issue: 2 | Pages: 95-106

10.1177/26345161241300480 Get It

Background: Pathologic reflux is a common debilitating digestive condition and anti-reflux surgery is an effective treatment option. Depending on the specifics of the procedure, anti-reflux surgery leads to distinct changes in the endoscopic appearance of the esophagogastric junction (EGJ). This American Foregut Society (AFS) white paper develops nomenclature for describing the endoscopic characteristics of the EGJ after commonly performed laparoscopic antireflux operations. Methods: The AFS Anti-Reflux Barrier Collaborative analyzed the anatomic manipulation and corresponding endoscopic appearance of the EGJ after commonly performed anti-reflux surgery including: (1) 360° anterior/posterior (AP) fundoplication (Nissen); (2) posterior partial fundoplication (Toupet); (3) anterior partial fundoplication (Watson, Dor); (4) magnetic sphincter augmentation; and (5) concomitant hiatal hernia repair with transoral fundoplication (cTIF). Results: Characteristics common to the anti-reflux surgery procedures include restoration of intra-abdominal esophageal length and crural diaphragm repair such that the hiatal aperture is no longer visible in the retroflexed endoscopic view. With regard to the geometry of anti-reflux procedures, the Collaborative established that when evaluated endoscopically in retroflection, the surgically constructed valve should be described in reference to the angle of His and the extent of anatomic change described in terms of (1) the depth of the anterior and posterior grooves, (2) the apposition of the valve collar to the endoscope, (3) the length of the valve, and (4) the position of the squamocolumnar junction relative to the lip of the valve. Conclusions: Current anti-reflux operations share much in common but employ varying degrees of valvular reconstruction leading to distinct endoscopic characteristics. Developing a consistent nomenclature for describing the appearance of the post-surgical valve is essential to develop a better understanding of how variables such as the tightness of the hiatal repair, tightness of the valve collar, and length of the valve can impact the outcome of anti-reflux surgery and predict reflux recurrence.
Response to: Correspondence on Comparative analysis of single plane and biplane angiography systems for mechanical thrombectomy for acute ischemic stroke: a systematic review and meta-analysis by Zhang et al
Orscelik, Atakan , Ghozy, Sherief , Brinjikji, Waleed , Kallmes, David F. , Ghozy, Sherief , Orscelik, Atakan

Journal of NeuroInterventional Surgery | November 20, 2024 | Volume: 17 | Issue: 8 | Pages: 909-910

10.1136/jnis-2024-022756 | PMID 39567190 Get It

Blood Plasma Methylated DNA Markers in the Detection of Lymphoma: Discovery, Validation, and Clinical Pilot
Witzig, Thomas E. , Taylor, William R. , Burger, Kelli N. , Devens, Mary E., Arndt, Jacquelyn R., O'Connell, Maria C., Novak, Anne J. , Hennek, Jacquelyn, Katerov, Viatcheslav E. , Allawi, Hatim T. , Dao, Linda N. , Witzig, T.E. , Cerhan, James R , Katerov, Viatcheslav E , Jevremovic, Dragan , Mahoney, Douglas W. , Bamlet, William R. , Foote, Patrick H. , Doering, Karen A. , Berger, Calise K. , Cerhan, James R. , Jevremović, Dragan , Graham, Rondell P. , Kisiel, John B.

American Journal of Hematology | November 20, 2024 | Volume: 100 | Issue: 2 | Pages: 218-228

10.1002/ajh.27533 | PMID 39564730 Get It

ABSTRACT Lymphoma is one of the leading causes of cancer and cancer deaths and yet has not been amenable to population screening. The role of methylated DNA markers (MDMs) in the detection of lymphoma has not been extensively studied. We aimed to discover, validate, and test tissue–derived MDMs of lymphoma in archival plasma specimens. Reduced representation bisulfite sequencing (RRBS) was performed on a discovery set of frozen tissues. MDMs identified were converted to methylation–specific PCR assays and validated on independent formalin–fixed, paraffin‐embedded (FFPE) tissues. Target enrichment long–probe quantitative‐amplified signal (TELQAS) assays were developed and assayed in plasma–extracted, bisulfite‐converted DNA from independent treatment‐naïve lymphoma patients and healthy controls. Prediction of cancer status was modeled using random forest model with in silico cross‐validation. After discovery and validation in tissue, 16 TELQAS assays ( ZNF503 , VWA5B1 , HOXA9 , GABRG3 , ITGA5 , MAX.chr17.7190 , BNC1 , CDK20 , MAX.chr4.4069 , TPBG , DNAH14 , SYT6 , CACNG8 , FAM110B , ADRA1D , and NRN1 ) were selected for testing in plasma. These detected 78% (95% CI, 74%–82%) of lymphoma cases at 90% specificity. Excluding marginal zone and T‐cell lymphomas, sensitivity increased to 84% (80%–88%). MDMs in plasma show promise to detect lymphoma and are candidates for inclusion in multi‐cancer detection studies.
Prolonged Water-Only Fasting Followed by a Whole-Plant-Food Diet Is a Potential Long-Term Management Strategy for Hypertension and Obesity
Zeiler, Evelyn , Gabriel, Sahmla , Ncube, Mackson, Thompson, Natasha , Newmire, Daniel E., Scharf, Eugene , Goldhamer, Alan , Myers, Toshia R. , Newmire, Daniel , Scharf, Eugene L , Goldhamer, Alan C , Myers, Toshia R

Nutrients | November 20, 2024 | Volume: 16 | Issue: 22 | Pages: 3959

10.3390/nu16223959 | PMID 39599745 Get It

Objective: This single-arm, pre–post interventional trial (clinicaltrials.gov, NCT04515095) investigates the safety, feasibility, and potential effectiveness of prolonged water-only fasting followed by a whole-plant-food diet in the long-term management of hypertension and other cardiometabolic disorders. Methods: Safety was assessed based on adverse events (AEs) that were recorded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Feasibility was assessed based on retention rate, ability to complete minimal fast length, and intervention acceptability. Twenty-nine participants with stage 1 and 2 hypertension and without type 2 diabetes were enrolled from a residential fasting center. Results: Study retention was 100% at the end of the refeed and 93% at the six-week follow-up visit. Median (range) fasting and refeeding duration were 11 (7–40) and 5 (3–17) days, respectively, and 90% of participants were able to complete at least 7 days of fasting. The majority of AEs were mild (grade 1) and transient and there were no higher-grade or serious AEs. At the end of the intervention, median systolic/diastolic blood pressure had normalized to below 130/80 mmHg, body weight reduced by >5%, and anti-hypertensive medication was completely discontinued. These results were sustained for at least six weeks and potentially up to one year. Conclusions: Our data suggest that the intervention may be a feasible, well-tolerated, low-risk option for lowering and managing high blood pressure, excess body weight, and other cardiometabolic disorders in people with stage 1 and 2 hypertension.